Top entities: Silo Pharma, International — European Patent Office, Eric Weisblum.

What category does this event fall under?

Regulatory — classified as patent grant.

What is the sentiment of coverage?

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Aug 10, 2026. Coverage continues to evolve.

Regulatory patent grant

Silo Pharma Granted European PTSD Patent

Q: When did this event occur?

First reported Aug 10, 2026; last updated Aug 10, 2026.

Q: What is the market impact?

General. The patent grant strengthens Silo Pharma's intellectual property position for its lead candidate SPC-15, potentially enhancing its valuation and competitive advantage in the PTSD treatment market.

Analysis based on 6 articles · First reported Aug 10, 2026 · Last updated Aug 10, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The patent grant strengthens Silo Pharma's intellectual property position for its lead candidate SPC-15, potentially enhancing its valuation and competitive advantage in the PTSD treatment market. This positive regulatory development may boost investor confidence in Silo Pharma's pipeline and future commercialization prospects.

Biopharmaceuticals Intellectual Property

Event Summary

On August 10, 2026, Silo Pharma announced that the International — European Patent Office (EPO) granted European Patent No. EP3952852, titled 'Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress.' The patent covers methods of preventing stress-induced fear, depressive-like behavior, and associated affective disorders by administering selected serotonin 4 (5-HT4) receptor agonists before exposure to a stressor. This patent protects the preventative approach of Silo Pharma's lead candidate SPC-15, an intranasal nose-to-brain treatment for PTSD and stress-induced affective disorders. Silo Pharma holds an exclusive license for the European patent from Columbia University. The company's CEO, Eric Weisblum, emphasized that this strengthens the intellectual property moat around SPC-15 and extends protection in the European market, complementing patent protection granted and pending in five other major global markets. Silo Pharma is a developmental-stage biopharmaceutical company focused on underserved conditions including stress-induced psychiatric disorders, chronic pain, and CNS diseases.

Key Actions

100 International — European Patent Office granted patent Silo Pharma

Entities Involved

stock

Silo Pharma

Silo Pharma is the patent holder and developer of SPC-15. The European patent grant strengthens its IP portfolio and supports its strategy to commercialize the preventative PTSD treatment, potentially increasing its market value.

Importance 100.0 Sentiment 30.0

govactor

International — European Patent Office

The EPO granted the patent, validating the novelty of Silo Pharma's preventative approach. This action reinforces the EPO's role in granting intellectual property rights, with no direct market impact on the EPO itself.

Importance 80.0 Sentiment 0.0

per

Eric Weisblum

As CEO of Silo Pharma, Eric Weisblum announced the patent grant and highlighted its strategic importance. His leadership is central to the company's IP strategy and communication with investors.

Importance 40.0 Sentiment 10.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard